Ultragenyx Pharmaceutical Inc. reaffirmed earnings guidance for the year 2024. For the full year 2024, the company reaffirms: Total revenue in the range of $500 million to $530 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.53 USD | -0.81% | +1.39% | -13.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.15% | 3.48B | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024